ARCON: accelerated radiotherapy with carbogen and nicotinamide in non small cell lung cancer: a phase I/II study by the EORTC.

[1]  M. Bolla,et al.  Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  M. Parmar,et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial , 1997, The Lancet.

[3]  J. Kaanders,et al.  Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. , 1997, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  J. Kaanders,et al.  A convenient and reliable method for carbogen breathing in man. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  M. Stratford,et al.  Pharmacokinetics of varying doses of nicotinamide and tumour radiosensitisation with carbogen and nicotinamide: clinical considerations. , 1993, British Journal of Cancer.

[6]  P. Sminia,et al.  Feasibility of curative radiotherapy with a concomitant boost technique in 33 patients with non-small cell lung cancer (NSCLC) , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[7]  J. Overgaard,et al.  Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. , 1993, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  J. Overgaard,et al.  Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. , 1990, Cancer research.

[9]  J. Overgaard,et al.  Radiosensitization by nicotinamide in tumors and normal tissues: the importance of tissue oxygenation status. , 1989, International journal of radiation oncology, biology, physics.

[10]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[11]  J. Fowler,et al.  ARCON--current status: summary of a workshop on preclinical and clinical studies. , 1997, Acta oncologica.

[12]  P. Hoskin,et al.  Nicotinamide pharmacokinetics in normal volunteers and patients undergoing palliative radiotherapy. , 1996, Acta oncologica.

[13]  R. Henriksson,et al.  Acute effects of accelerated radiotherapy in combination with carbogen breathing and nicotinamide (ARCON). , 1994, Acta oncologica.